Fibromuscular Dysplasia

TUESDAY, April 11, 2023 (American Heart Association News) -- Shelley Davis packed shorts, bathing suits and sunscreen for a weeklong cruise with her husband, Greg, and their 13- and 15-year-old daughters. The morning before boarding the ship in Port Canaveral, Florida, the family from Mesa, Arizona, soaked up the sunshine and played in an arcade. When it came time to board the bus for the cruise terminal, Shelley had a headache. Once on board the ship, she headed straight to her stateroom for a nap. "I took the girls out to look around the ship and when we went back to the room, Shelley was really ill," Greg said. She joined her family on the main deck for a life jacket drill. Greg planned to find a nurse once the demonstration was complete. However, he noticed that when he asked her questions, she answered with only yes or no. Sensing something was off, he asked, "Do you know what your name is?" "Yes," she said. "Tell me your name," Greg said. Shelley just looked at him. He immediately went for help. Shipboard medics took Shelley to the infirmary. An exam determined she needed advanced medical care. Fortunately, the ship was still docked. An ambulance was called and Shelley was transported to the nearest hospital. By the time she reached the emergency room, the right side of her face was drooping and she couldn't move her right side. Even though Shelley worked as an occupational therapist helping stroke survivors during their recovery, the then-46-year-old never considered that she was having a stroke. Further examination revealed that the cause was a carotid artery dissection, when the layers of the carotid artery in the neck separate, and blood flow to the brain is compromised. Shelley had 100% blockage of blood flow. She was airlifted to a nearby trauma hospital. Doctors gave her a 20% chance of survival. "When we saw her in the hospital, the reality set in that this was a life-or-death situation," Greg said. Shelley had emergency surgery to restore blood flow to her brain. The stroke was attributed to fibromuscular dysplasia, a rare disease that causes medium-sized arteries to narrow, blocking blood flow and possibly leading to aneurysms. Instead of spending a week cruising between Caribbean islands and enjoying shipboard activities, Shelley was in the intensive care unit. But she knew she was lucky to be alive. "I remember waking up and I could move my right arm slightly, and I knew that was a really good sign for recovery," she said. "I was so grateful that it happened when it did and not hours later when we were out to sea." Surgery was just the first step in a long recovery process. Shelley returned home to Arizona and received months of outpatient therapy. Even though she was able to regain strength in her right side, speech remained a challenge. She relied on her family to help her communicate. "It was very frustrating when the phone would ring at home," she said. "I couldn't answer it because I couldn't communicate. Or when I had the strength to go grocery shopping, I couldn't go to the deli and tell them what I wanted. It motivated me to do another set of reps for speech exercises." Three years after her stroke, which happened in 2015, Shelley returned to work, helping stroke survivors relearn how to do everyday activities. She tells them about her own experience to help motivate them. "My patients get so frustrated because they want to be totally recovered as fast as possible, but I know from being in that situation that you have to take it a day at a time, a week at a time," she said. "Every year, I'm still progressing with speech and strength. It's nice to have that unique perspective of being a health care provider and a stroke survivor because I can empathize and show them that recovery is possible." American Heart Association News covers heart and brain health. Not all views expressed in this story reflect the official position of the American Heart Association. Copyright is owned or held by the American Heart Association, Inc., and all rights are reserved. By Jodi Helmer, American Heart Association News Posted April 2023

A new study finds a shared complex genetic architecture that explains why when one family member develops fibromuscular dysplasia, the risk of a male member of that family developing an abdominal aortic aneurysm is significantly higher. Researchers say the findings also support that screening for abdominal aortic aneurysm in male relatives of patients with FMD may be useful, along with currently established AAA screening guidelines. One disease is more common in people assigned female at birth, while the other is more common in people assigned male at birth. But a new publication details a "shared complex genetic architecture" between the cardiovascular conditions that could explain why, when one member of a family develops fibromuscular dysplasia, another may develop an abdominal aortic aneurysm. "We used complementary genetic approaches to validate the relationship between these two highly sex-biased conditions, raising some interesting questions regarding sex differences relating to a common, shared genetic risk profile," said senior author Santhi K. Ganesh, M.D., an associate professor of internal medicine and human genetics, and a cardiologist at the University of Michigan Health Frankel Cardiovascular Center. Ganesh and colleagues analyzed family histories from 73 people with FMD and 463 of their first-degree relatives who volunteered to participate in clinical research. They discovered that, in a family where one person had FMD, the risk of a male member of that family developing an abdominal aortic aneurysm was significantly higher. For example, the father of a person with FMD was twice as likely to experience AAA, according to results published in Circulation: Genomic and Precision Medicine. The research team then compared a new polygenic risk score for FMD and established polygenic risk scores for AAA to verify a shared genetic basis for both diseases, Ganesh says. The results point to specific genes that may underlie both diseases, providing new biological understanding of vascular diseases. The findings also support that screening for abdominal aortic aneurysm in male relatives of patients with FMD may be useful, along with currently established AAA screening guidelines.

Demand for renal denervation procedures is anticipated to be aided by various authorities and government organizations increasing funding for R&D initiatives for renovascular hypertension treatment. Fact.MR – A Market Research and Competitive Intelligence Provider: Renal Denervation technologies have witnessed impressive growth in the past due to surge in prevalence of hypertension patients. Moreover, market is also driven by its minimally-invasive procedure for hypertension treatments. Renal denervation is a microsurgical solution for hypertension. Radiofrequency ablation is the process that helps burning the neurons in the renal arteries. Once blood pressure is reduced, nerve stimulation is decreased. This is commonly used to get better results when drug treatment hasn't worked to relieve symptoms. With the help of ultrasound or radiofrequency pulses, the nerves that line the renal artery wall are destroyed. Moreover, a reduction in sympathetic kidney activity lowers blood pressure. Also, the renal denervation devices are expected to witness high demand due to rising prevalence of chronic disorders including obesity in both, children and adults. As per the statistic from World Health Organization (WHO), more than 39 million children under the age of five were overweight in 2020. Also, high leptin levels in obese individuals might lead to hypertension by stimulating the formation of blood vessels in the hypothalamus. For more insights into the Market, Request Brochure of this Report However, inadequate clinical data is one of the factors restricting the growth of renal denervation technologies market, which makes it challenging to obtain regulatory body approval for new products. Moreover, market is also restricted due to lack of skilled professionals. Moreover, risk of infection following surgery is one of the main concerns that can limit the demand. But, introduction of new products in this area is expected to aid the expansion of the market. Also, the surge in prevalence of drug-resistant hypertension cases in various regions such as North America, Europe could drive the growth of the market. Market Trends: Surge in funding for treatment of renal disorders Various government authorities and organizations are increasing funding for R&D initiatives for renovascular hypertension treatment. Moreover, advancements in the devices could also fuel the growth of the industry. Apart from this, various factors that are boosting the adoption of the renal denervation method is that it lessens the renal artery injury. Various patients because of its effectiveness prefer this method. Moreover, government organizations are incorporating technology into these kinds of health practices and also offering opportunities in renal denervation industry. For Comprehensive Insights Ask An Analyst Here New entrants attempting to create reliable systems New market entrants are focusing on technological advancements in Renal Denervation Technologies. Moreover, new companies are continuously focus on reliable systems for reducing the difficulties associated with high blood pressures and hypertension. For instance, A start-up based in Israel – SoniVie - received FDA approval for its novel treatment for hypertension. Moreover, patients with hypertension can benefit from renal artery denervation using the advanced ultrasound technology TIVUS. Moreover, the main treatment made available by TIVUS, renal denervation, is a minimally invasive surgery that safely ablates renal artery nerves using high frequency, non-focused ultrasound energy. Moreover, this process lowers blood pressure by reducing nerve activity. Regional Market Growth Avenues Europe is expected to dominate the renal denervation technologies market. As per a research study, Over 40% of Europeans over the age of 25 have hypertension, and 10% of those have medication-resistant hypertension. Moreover, numerous renal denervation activities with CE authorization are available in Europe. Also, growing R&D efforts to create effective technologies for renal artery stenosis are the main drivers boosting the market expansion. In the meanwhile, increased incidences of uncontrolled hypertension, changing lifestyle among the populace are expected to fuel market expansion in the US. Also, rapid growth of uncontrolled hypertension caused by rapid urbanization, and an increase in FDA approvals are major factors contributing to the market growth in the United States. Get Customization on this Report for Specific Research Solutions More Insights Available Fact.MR offers a unique perspective and actionable insights on the coatings for Renal Denervation Technologies Market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031. The research study is based on the basis of Product (Symplicity, Vessix, EnligHTN, ParadiseI, beris & Others) By Technology (Radiofrequency-based, Ultrasound-based & Micro-infusion-based) By End-User and By Region – Global Market Insights 2022 to 2026 Explore Fact.MR’s Coverage on the Healthcare Domain Renal Artery Stenosis Treatment Market - Renal artery stenosis is the narrowing of the renal artery that carries blood to the kidneys. The narrowing of the renal artery obstructs blood flow, resulting in renovascular hypertension, high blood pressure, and kidney damage. Atherosclerosis and fibromuscular dysplasia are the major causes of renal artery stenosis. Renal Artery Embolization Market - The renal arteries take a large volume of blood to be filtered by the kidneys. The renal artery embolization technique is used mainly to treat urological and neurological diseases. The renal artery embolization technique is a minimal invasive procedure that terminates the blood flow completely or partially. Renal Drugs Market - Renal diseases are becoming a significant health issue among the general population. Renal drugs are majorly used for kidney disease treatment. The treatment for kidney diseases totally depends on the stage of chronic kidney disease. The main treatments which are generally provided for chronic kidney disease are lifestyle changes, renal drugs, dialysis, and kidney transplantation. Renal Denervation Technologies Market - Demand for radiofrequency-based technology is expected to increase at 35% CAGR over the coming years. It is anticipated that the excellent efficacy of radiofrequency-based technology, which has been demonstrated in various trials, would boost the significance of these devices across geographies. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. 80% of Fortune 1000's trusts us in critical decision making. We provide both qualitative and quantitative research, spanning market forecast, market segmentation, competitor analysis, and consumer sentiment analysis. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Follow Us: LinkedIn | Twitter